Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Rhea-AI Summary
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, at 9:00 a.m. EDT. A live webcast will be available via the Investors “Events & Presentations” section on the company’s website.
Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Lead candidate CardiolRx™ is being evaluated in the Phase III MAVERIC trial for recurrent pericarditis and has Orphan Drug Designation from the U.S. FDA. The completed Phase II ARCHER study assessed CardiolRx™ in acute myocarditis. Cardiol is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart disease, including heart failure.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Phase II data publication | Positive | +8.5% | Phase II recurrent pericarditis data published as Phase III enrollment neared completion |
| Jul 09 | Conference fireside chat | Neutral | -0.8% | Participation announced for B. Riley Securities investor summit |
| Jun 25 | Annual meeting results | Neutral | +1.0% | Shareholders approved management resolutions and appointed BDO Canada LLP |
| Jun 23 | Annual meeting webcast | Neutral | -0.9% | Virtual annual meeting scheduled for June 24, 2026 |
| May 14 | Conference fireside chat | Neutral | +0.7% | Participation announced for H.C. Wainwright investor conference |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and shareholder-meeting notices had mixed reactions, including -0.8%, -0.94%, +0.74%, and +0.97%; the Phase II publication was followed by +8.49%.
Key Terms
anti-fibrotic medical
inflammasome pathway activation medical
orphan drug designation regulatory
small-molecule drug candidate technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Canaccord Genuity's 46th Annual Growth Conference
When: Tuesday, August 11 at 9:00 a.m. EDT.
Where: InterContinental Boston Hotel, in Griffin/Robinson
A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-genuitys-46th-annual-growth-conference-302843548.html
SOURCE Cardiol Therapeutics Inc.